SUVEN LIFE SCIENCES Financial Statement Analysis
|
||
|
The Revenues of SUVEN LIFE SCIENCES have decreased by -13.63% YoY .
The Earnings Per Share (EPS) of SUVEN LIFE SCIENCES has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SUVEN LIFE SCIENCES Last 5 Annual Financial Results
[BOM: 530239|NSE : SUVEN]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹12 Cr | ₹14 Cr | ₹12 Cr | ₹13 Cr | ₹14 Cr |
| Expenses | ₹140 Cr | ₹139 Cr | ₹134 Cr | ₹93 Cr | ₹130 Cr |
| Operating Profit (Excl OI) | ₹-128 Cr | ₹-126 Cr | ₹-122 Cr | ₹-80 Cr | ₹-116 Cr |
| Other Income | ₹21 Cr | ₹8.45 Cr | ₹1.60 Cr | ₹7.75 Cr | ₹14 Cr |
| Interest | ₹0.30 Cr | ₹0.41 Cr | ₹0.67 Cr | ₹0.94 Cr | ₹0.55 Cr |
| Depreciation | ₹6.50 Cr | ₹6.54 Cr | ₹4.39 Cr | ₹4.35 Cr | ₹4.17 Cr |
| Profit Before Tax | ₹-106 Cr | ₹-118 Cr | ₹-122 Cr | ₹-77 Cr | ₹-106 Cr |
| Profit After Tax | ₹-105 Cr | ₹-118 Cr | ₹-122 Cr | ₹-72 Cr | ₹-94 Cr |
| Consolidated Net Profit | ₹-105 Cr | ₹-118 Cr | ₹-122 Cr | ₹-72 Cr | ₹-94 Cr |
| Earnings Per Share (Rs) | ₹-4.82 | ₹-5.42 | ₹-8.39 | ₹-5.67 | ₹-7.40 |
| PAT Margin (%) | -898.63 | -873.52 | -1,029.99 | -535.31 | -653.62 |
| ROE(%) | -32.56 | -50.17 | -145.90 | -67.29 | -49.27 |
| ROCE(%) | -32.78 | -49.94 | -117.81 | -60.09 | -54.67 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 |
Key Financials |
||
| Market Cap | : | ₹ 2,634.6 Cr |
| Revenue (TTM) | : | ₹ 8.4 Cr |
| Net Profit(TTM) | : | ₹ -146.0 Cr |
| EPS (TTM) | : | ₹ -6.7 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUVEN LIFE SCIENCES | -4.8% | -8.1% | 45.5% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.4% | -7.1% | 48% |
| CIPLA | -3.5% | -5.2% | 18% |
| DR REDDYS LABORATORIES | -3.9% | -10.1% | 10.1% |
| ZYDUS LIFESCIENCES | -0.3% | -7.3% | 52.2% |
| DIVIS LABORATORIES | 1.5% | -2.1% | 63% |
| MANKIND PHARMA | -2.3% | -3% | 39.6% |
| TORRENT PHARMACEUTICALS | -1.8% | -10.2% | 51.3% |
| LUPIN | -2.4% | -6.4% | 73.9% |
SUVEN LIFE SCIENCES Revenues
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | -13.63 % |
| 5 Yr CAGR | -5.10 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹12 Cr | -13.63 | |
| Mar2023 | ₹14 Cr | 14.31 | |
| Mar2022 | ₹12 Cr | -12.12 | |
| Mar2021 | ₹13 Cr | -6.50 | |
| Mar2020 | ₹14 Cr | - | |
SUVEN LIFE SCIENCES Operating Profit
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹-128 Cr | Negative | |
| Mar2023 | ₹-126 Cr | Negative | |
| Mar2022 | ₹-122 Cr | Negative | |
| Mar2021 | ₹-80 Cr | Negative | |
| Mar2020 | ₹-116 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | -1093.52% | Negative | |
| Mar2023 | -928.89% | Negative | |
| Mar2022 | -1032.16% | Negative | |
| Mar2021 | -593.12% | Negative | |
| Mar2020 | -802.75% | - | |
SUVEN LIFE SCIENCES Profit After Tax
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹-105 Cr | Negative | |
| Mar2023 | ₹-118 Cr | Negative | |
| Mar2022 | ₹-122 Cr | Negative | |
| Mar2021 | ₹-72 Cr | Negative | |
| Mar2020 | ₹-94 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | -898.63 % | Negative | |
| Mar2023 | -873.52 % | Negative | |
| Mar2022 | -1029.99 % | Negative | |
| Mar2021 | -535.31 % | Negative | |
| Mar2020 | -653.62 % | - | |
SUVEN LIFE SCIENCES Earnings Per Share (EPS)
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹-4.82 | Negative | |
| Mar2023 | ₹-5.42 | Negative | |
| Mar2022 | ₹-8.39 | Negative | |
| Mar2021 | ₹-5.67 | Negative | |
| Mar2020 | ₹-7.40 | - | |
SUVEN LIFE SCIENCES Return on Capital Employed (ROCE)
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | -32.78% | Negative | |
| Mar2023 | -49.94% | Negative | |
| Mar2022 | -117.81% | Negative | |
| Mar2021 | -60.09% | Negative | |
| Mar2020 | -54.67% | - | |
SUVEN LIFE SCIENCES Share Price vs Sensex
| Current Share Price | : | ₹120.8 |
| Current MarketCap | : | ₹ 2,634.6 Cr |
| Updated EOD on | : | Nov 19,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUVEN LIFE SCIENCES | -4.8% |
-8.1% |
45.5% |
| SENSEX | -2.4% |
-4.2% |
19.5% |
SUVEN LIFE SCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE HEALTHCARE | -2.5% | -4% | 46.8% |
| S&P BSE MIDSMALLCAP | -2.9% | -7% | 35.6% |
| S&P BSE SMALL CAP | -3.3% | -7.2% | 35.2% |
No NSE index found
You may also like the below Video Courses
FAQ about SUVEN LIFE SCIENCES Financials
How the annual revenues of SUVEN LIFE SCIENCES have changed ?
The Revenues of SUVEN LIFE SCIENCES have decreased by -13.63% YoY .
How the Earnings per Share (EPS) of SUVEN LIFE SCIENCES have changed?
The Earnings Per Share (EPS) of SUVEN LIFE SCIENCES has decreased by Negative YoY .
Check out Intrinsic Value of Peers of SUVEN LIFE SCIENCES
Compare Stock Analytics of Peers of SUVEN LIFE SCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
